Translating the Latest Data for More Durable Anti-VEGF Therapies
to Treat nAMD in
Clinical Practice
This American Academy of Ophthalmology initiative provides ophthalmologists with a focused update on the latest data surrounding long-acting intravitreal anti-VEGF agents for neovascular age-related macular degeneration (nAMD).
This CME-accredited collection features:
Expert panel discussions on emerging evidence and therapeutic strategies
Real-world patient cases contextualizing clinical trial outcomes
Click on the activities below to explore valuable insights and clinical decision-making around:
Therapy selection based on patient characteristics and disease progression
Individualized dosing strategies and treatment intervals
Monitoring response and adjusting therapy to reduce treatment burden
Infographic
Credit Hours: 0.50 (30 min)
Case Consult
Credit Hours: 0.25 (15 min)
Case Consult
Credit Hours: 0.25 (15 min)
Case Consult
Credit Hours: 0.25 (15 min)
Patient Simulation
Credit Hours: 0.50 (30 min)
Translating the Latest Data for More Durable Intravitreal Anti-VEGF Therapies to Treat nAMD in Clinical Practice
Webinar
Credit Hours: 0.50 (30 min)
COMING SOON
Safety of the More Durable Anti-VEGF Therapies: Findings From Treatment of nAMD in Clinical Trials and Real-World Practice
Webinar
Credit Hours: 0.50 (30 min)
COMING SOON
Case Studies in Personalizing Treatment for nAMD Using More Durable Anti-VEGF Therapies
Webinar
Credit Hours: 0.50 (30 min)
COMING SOON
Initiating More Durable Anti-VEGF Therapies in Patients With nAMD
Patient Simulation
Credit Hours: 0.25 (15 min)
COMING SOON
Switching to a More Durable Anti-VEGF Agent for nAMD
Patient Simulation
Credit Hours: 0.25 (15 min)
COMING SOON
Webinar
Credit Hours: 0.50 (30 min)
This activity has expired and is no longer available for credit
This website uses cookies to improve your experience. If you continue to use this site, you agree with it.
Ok